Results 81 to 90 of about 1,716,154 (283)

Programmable Nanobody‐Targeting Chimeras Enable Intracellular Viral Protein Degradation

Advanced Science, EarlyView.
Nab‐TAC enables targeted degradation of HBV surface antigen (HBsAg) in vivo. By fusing nanobody‐based recognition domains with programmable proteasome‐recruiting degradation signals, Nab‐TAC reduces HBsAg levels in a hydrodynamic HBV mouse model. ABSTRACT Chronic hepatitis B virus (HBV) infection remains a major global health challenge, largely because
Max Yu‐Chen Pan, Ting‐Hui Lee, Tzu‐Ning Peng, Eva Yi‐Hsuan Wu, Yu‐Ting Chiu, Chih‐Chien Chiu, Hong Vinh Nguyen, Yuan‐Shao Pao, Ming‐Hong Chao, Richard Kuan‐Lin Lee, Han‐Chung Wu, Lily Hui‐Ching Wang   +11 more
wiley   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

Integrated Single‐Cell and TCR Profiling Reveals Protection‐Associated CD8+ T Cell Subsets Linked to Viral Control in PRRSV

Advanced Science, EarlyView.
PRRSV vaccine‐mediated protection is associated with clonally expanded cytotoxic CD8+ T cell subsets driven by viral structural proteins and supported by innate TLR4/TLR8 signaling and CD4+ T cell help, whereas non‐protective responses are characterized by dysfunctional exhausted‐like CD8+ T cells linked to poor viral control.
Can Kong, Siang Chen, Maolin Li, Meng Wang, Hailin Zhang, Bolun Zhou, Zhenhua Xie, Chen Wang, Peng Gao, Jianjun Luo, Hanchun Yang, Runsheng Chen, Dongdong Zhang, Jie Li, Jun Han   +14 more
wiley   +1 more source

Chimeric antigen receptor-based therapies beyond cancer [PDF]

Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology.
Velasco de Andrés, María, Lozano, Francisco, Català, Cristina, Gutiérrez Hernández, María del Mar, Isamat, Marcos, Carrillo-Serradell, Laura, Muñoz Sánchez, Guillermo   +6 more
core   +1 more source

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

Advanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan, Xuan Liu, Qian‐Fang Meng, Lei Cao, Rongrong Li, Yangtao Xu, Jing Zhang, Chenchen Zhao, Lang Rao, Chen Yu   +9 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy and bispecific antibodies in the treatment of lymphoma for human immunodeficiency virus-infected patients: A systematic review

SAGE Open Medicine
Background: Chimeric antigen receptor T-cell therapy has emerged as a highly effective treatment for relapsed and refractory lymphomas; however, its application in individuals with human immunodeficiency virus remains underexplored.
Alejandra Viera Plasencia, Jeremy I. Purow, Julia Steger, Alexander Brown-Whalen, Henna Qadri, Nicolas Duque Clavijo, Marco Ruiz-Andia   +6 more
doaj   +1 more source

Chimeric antigen receptor cell therapies: From anticancer immunity to tissue repair and neural regeneration

Originally developed as breakthroughs in cancer immunotherapy, Chimeric antigen receptor cell therapies have recently attracted attention because of their potential to promote tissue repair and functional restoration.
Aarchi A. Bharadia, Vibha G. Kanjani, Kashvy R. Morakhia   +2 more
core   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

Advanced Science, EarlyView.
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li, Minghua Xiang, Qiuyang Xu, Jiahao Liu, Xiaofei Jiao, Wei Mu, Xiaoying Lv, Kangjia Tao, Yu Xu, Dongchen Zhou, Wenjian Gong, Danmei Yan, Yixin Hu, Sen Xu, Bingbing Zhao, Jundong Li, Yongkang Gai, Guang Hu, Li Zhu, Qinglei Gao, Yong Fang   +20 more
wiley   +1 more source

Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis

Advanced Science, EarlyView.
Engineered macrophages programmed in situ by LNP‐delivered IL‐6/4 fusion and LL37 mRNAs simultaneously dampen cytokine storm, promote M2‐like repair, and enhance direct bacterial killing in sepsis. This combinatorial strategy restores T cell and macrophage function, lowers organ bacterial burden, and improves survival, highlighting a precision, host ...
Tianyang Jie, Zheyu Zhang, Hao Zhang, Linke Bian, Penglong Zheng, Sijia Zhou, Minqi Wang, Mingyu Qu, Yufei Wang, Xinhua Qu, Bing Yue   +10 more
wiley   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

Advanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng, Lei Zheng, Rongkun Tao, Sirui Zheng, Yanke Zhong, Yongxia Niu, Peng Zhang, Xiang Ma, Chen Yang, Min Zhang, Fuyu Duan, Jing Yang, Xuan Wei, Xiang Zhou, Zhenbiao Yang, Zhaoxi Sun, Qizhou Lian   +16 more
wiley   +1 more source